adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count)
- RxCUI
- 2668489
- RxNorm name
- adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count)
- Display name
- adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count)
- Full name
- adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count)
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:58
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761219 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Yuflyma | ADALIMUMAB-AATY | CELLTRION USA, Inc. | 526d626f-8c9f-496c-b838-00a73bb36383 | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | 2668489 |
| Adalimumab | ADALIMUMAB-AATY | CELLTRION USA, Inc. | c44365e9-d470-4e35-978d-8565a9e3471e | 2026-07-08 | Boxed warning, Warnings, Adverse reactions | 2668489 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 526d626f-8c9f-496c-b838-00a73bb36383 | adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count) | PSN | 13 | These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe | 20251028 |
| 526d626f-8c9f-496c-b838-00a73bb36383 | adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count) | SY | 13 | These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe | 20251028 |
| 526d626f-8c9f-496c-b838-00a73bb36383 | {3 (0.8 ML adalimumab-aaty 100 MG/ML Auto-Injector) } Pack | GPCK | 13 | These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe | 20251028 |
| c44365e9-d470-4e35-978d-8565a9e3471e | adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count) | SY | 6 | These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab). | 20251028 |
| c44365e9-d470-4e35-978d-8565a9e3471e | adalimumab-aaty Auto-Injector 80 MG/0.8 ML Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count) | PSN | 6 | These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab). | 20251028 |
| c44365e9-d470-4e35-978d-8565a9e3471e | {3 (0.8 ML adalimumab-aaty 100 MG/ML Auto-Injector) } Pack | GPCK | 6 | These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab). | 20251028 |